Unique, practical knowledge for nurses responsible for daily management of patients with cardiovascular disease, diabetes and related conditions.

Topic:

Monday, 28 May 2012

As the use of insulin therapy becomes more common in the ever-growing population of people with diabetes, practice nurses need to be aware of the range of insulins now available and how they work as they take on more responsibility for the management of these patients. In this article, we look at the production and role of insulin in the body and how type 1 and type 2 diabetes affects this. Moving on to newer insulins, we review how longer-acting insulins are used to mimic the characteristics of natural background insulin, the role of shorteracting insulins available for mealtime bolus doses, and the use of insulin mixtures in practice.

Category: Editorial
Wednesday, 10 February 2021

Professor Cliff Bailey and Professor Vinod Patel discuss type 2 diabetes and SGLT2 inhibitors in context plus managing glycaemic control and body weight.

Category: Webinars
Tuesday, 27 October 2009

In May 2009, NICE published recommendations on the use of newer agents for the control of blood glucose in type 2 diabetes. This guideline provides a partial update for NICE Clinical Guideline 66 on the management of type 2 diabetes that was published last year. These newer agents include the dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), the glucagon-like peptide-1 (GLP-1) mimetic exenatide and the long-acting insulin analogues (insulin detemir and insulin glargine).

Category: Editorial
Monday, 17 July 2017
Management of type 2 diabetes continues to be very challenging. Adherence with therapy is poor, due in part to the number of medications and the high frequency they need to be taken each day. PillTime is a new system which makes managing medicines easier and is ideal for those on multiple medicines and active lifestyles.
Category: Have You Heard
Monday, 17 July 2017
A new study led by the University of Leicester suggests that one in three people who suffer from high blood pressure are failing to take medication as prescribed by their healthcare professionals. Non-adherence to antihypertensive treatment is a critical contributor to suboptimal blood pressure control.
Tuesday, 05 July 2016
Alirocumab (Praluent®) and evolocumab (Repatha®) have received final approval from NICE for the treatment of adults with primary hypercholesterolaemia or mixed dyslipidaemia to help reduce the risk of cardiovascular disease.
Category: Have You Heard
Friday, 13 May 2016
Alirocumab (Praluent) and evolocumab (Repatha) have been recommended by NICE for the treatment of adults with primary hypercholesterolaemia or mixed dyslipidaemia to help reduce the risk of cardiovascular disease.
Category: Have You Heard
Thursday, 23 June 2016
Canagliflozin (Invokana™), dapagliflozin (Forxiga™) and empagliflozin (Jardiance™) have received final NICE approval in type 2 diabetes and are now available to patients with type 2 diabetes who cannot tolerate metformin, sulfonylurea or pioglitazone therapy and are not being controlled with diet and exercise.
Category: Have You Heard
Tuesday, 05 July 2016

A new Cochrane Review highlights the value of nurse-led titration of ACE inhibitors, beta-blockers and angiotensin II receptor blockers in patients with chronic heart failure. All-cause mortality and hospitalisations were lower in the nurse-led titration group compared with the usual care of titration by GPs.

Monday, 28 February 2005

Primary care nurses play a central role in the management of type 2 diabetes in the community. This includes helping patients to use their drug treatment correctly. Although many patients with type 2 diabetes initially respond well to weight loss and exercise, most require oral hypoglycaemics and half of all patients eventually require insulin to control their glucose levels in order to prevent the devastating long-term complications of inadequately controlled diabetes. Linda Goldie gives an up-to-date review of the newer insulins – including the insulin analogues, insulin lispro, insulin aspart and insulin glargine – that have been introduced.

Category: Editorial

Article search and filter